Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 113Breast Neoplasms 113Ovarian Neoplasms 69Triple Negative Breast Neoplasms 56Endometrial Neoplasms 42Fallopian Tube Neoplasms 40Squamous Cell Carcinoma of Head and Neck 39Lung Neoplasms 38Neoplasm Metastasis 35Stomach Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Neoplasms 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 21Head and Neck Neoplasms 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Carcinoma 15Colorectal Neoplasms 14Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Adenocarcinoma Of Esophagus 9Peritoneal Neoplasms 8Oropharyngeal Neoplasms 8Melanoma 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

Carboplatin 6pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pathologic Complete Response × Paclitaxel × 1 year × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡